Cargando…
Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
Autores principales: | Kori, S, Zhang, J, Kellerman, D, Armer, T, Goadsby, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620485/ http://dx.doi.org/10.1186/1129-2377-14-S1-P75 |
Ejemplares similares
-
Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
por: González-Hernández, Abimael, et al.
Publicado: (2018) -
Targeted 5-HT(1F) Therapies for Migraine
por: Vila-Pueyo, Marta
Publicado: (2018) -
Evaluation of a Monthly Coverage Maximum (Drug-Specific Quantity Limit) on the 5-HT1 Agonists (Triptans) and Dihydroergotamine Nasal Spray
por: Hoffman, Lauren, et al.
Publicado: (2003) -
Review: 5-HT(1), 5-HT(2), 5-HT(3) and 5-HT(7) Receptors and their Role in the Modulation of Pain Response in the Central Nervous System
por: Cortes-Altamirano, Jose Luis, et al.
Publicado: (2018) -
EHMTI-0125. Studying the permeability of the blood-brain barrier during migraine attacks using [11C]-dihydroergotamine
por: Schankin, C, et al.
Publicado: (2014)